GSK is acquiring 35Pharma for $950 million, and getting rights to HS235, a potential best-in-class PH treatment now in early clinical testing.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results